Becker's Hospital Review Names 100 Hospital and Health System CFOs to Know in 2019
CHICAGO, July 15, 2019 /PRNewswire-PRWeb/ -- Becker's Healthcare is pleased to recognize 100 hospital and health system CFOs to know.
The individuals featured on this list lead financial departments for large health systems as well as small community hospitals. Many play an integral role in their organization's strategic planning, growth and transactions; they have also been recognized by their peers and serve on the board of directors for community organizations.
Becker's Hospital Review accepted nominations and developed this list based on an editorial review process. Members of this list do not pay and cannot pay for inclusion. Contact Laura Dyrda at ldyrda(at)beckershealthcare.com with questions or comments on this list.
Note: This list is not an endorsement of included hospitals, health systems or associated healthcare providers, and organizations cannot pay for inclusion on this list. Executives are presented in alphabetical order.
Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the...
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZtm (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis...
The Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland.
The Annual General Meeting approved the financial statements for the financial year 1 January?31 December 2023 and resolved to discharge the members of the...
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted...
-- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.26 ---- Increases 2024 Full Year Guidance --
2024 adjusted diluted EPS of $2.26, up over 7% from $2.11 in the first quarter of 2023.Increases 2024 full year adjusted diluted EPS guidance by $0.10 to...
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first...
